CEO of FACC AG Robert Machtlinger talks about the company and presents recent figures and facts.
Marinomed Biotech AG is a biopharmaceutical company which was founded in 2006 as a spin-off of the University of Veterinary Medicine Vienna. Since then, the Company has grown successfully to around 50 employees in 2022. In February 2019, Marinomed went public in the prime market segment of the Vienna Stock Exchange. Since 2020, the company has been based at its new company site in Korneuburg, Lower Austria.
Marinomed is committed to the highest standards of transparency and maintains an open dialogue with its customers, shareholders, partners, and employees. Sustainable development and consistent improvement in environmental, social and governance (ESG) areas is a key priority for Marinomed.
#facc #stocks #travelstock
https://www.wienerborse.at/en/stock-prime-market/facc-ag-AT00000FACC2/
Stay updated on the Vienna Stock Exchange
➡️ Learn more: https://www.wienerborse.at/en/
➡️ Subscribe to our newsletters https://www.wienerborse.at/en/service/email-and-newsletter-service/
Follow us on social media and learn more
➡️ Twitter: https://twitter.com/wiener_boerse
➡️ LinkedIn: https://www.linkedin.com/company/wiener-borse-ag/
➡️ YouTube: https://www.youtube.com/channel/UCXqq_RYN8oNMEs1fUNefV-Q
